Trial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024 Future development of IV ganaxolone in refractory status epilepticus to be assessed following review of the final RAISE results Enrollment in the TrustTSC trial expected to complete mid-May with topline data on track for the first half of Q4... Read More